Regional Geographic Variations in Kidney Cancer Incidence Rates in European Countries

Li, Peng; Znaor, Ariana; Holcátová, Ivana; Fabiánovà, Eleonóra; Mateș, Dana; Wozniak, Magdalena B.; Ferlay, Jacques; Scélo, Ghislaine

doi:10.1016/j.eururo.2014.11.001

Cited by 62 publications

(38 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Пик заболеваемости приходится на возраст 40-60 лет. Частота выявления рака почки существенно варьирует в разных странах [1]. В России заболеваемость данной опухолью составляет 14,6 на 100 тыс.…”

Section: р е з о л ю ц и яunclassified

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

Motzer

Hutson

Glen

et al. 2015

The Lancet Oncology

827

567

View full text Add to dashboard Cite

Section: р е з о л ю ц и яunclassified

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

Motzer

Hutson

Glen

et al. 2015

The Lancet Oncology

827

567

View full text Add to dashboard Cite

“…[3] Similar trends have been observed in European registry databases, albeit granular data have demonstrated regional variations in detection rates. [14] Although the reasons are multifactorial, increased performance of routine abdominal imaging is the most likely cause. [15] However, while the rates of renal surgery have risen simultaneously with increased tumor detection, conflicting RCC survival and mortality trends have been reported, and it remains unclear if the dramatic increase in early detection and treatment over the past two decades has meaningfully impacted survival in patients with kidney cancer.…”

Section: Discussionmentioning

confidence: 99%

Understanding treatment disconnect and mortality trends in renal cell carcinoma using tumor registry data.

Smaldone¹,

Egleston²,

Hollingsworth³

et al. 2014

JCO

View full text Add to dashboard Cite

show abstract

“…Overall, the morality rate for RCC is 20–40% [1–3]. This high mortality rate for RCC is due to a lack of confirmed, efficacious therapeutic options for long-term tumor control.…”

Section: Introductionmentioning

confidence: 99%

The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry

Kim

Park

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

Objective To assess the prognostic roles of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue biomarkers in localized renal cell carcinoma (RCC). Methods Patients who underwent a nephrectomy during 1992–2015 and had a primary specimen of their kidney tumor were included. The nine tissue biomarkers were immunohistochemically stained on tissue microarrays of RCC, and the semi-quantitative H-score, including intensity score, was used to grade the sample. The Cox proportional hazards model was used to evaluate tissue markers significant for overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) after adjusting for significant clinicopathological parameters. Results Samples from 351 RCC patients were included. The mean age of the patients was 53.9 years; the rates of pathologic T1-2/≥T3 stage, Fuhrman 1+2/3+4 grade, recurrence, and death were 269/65(80.5/19.5%), 222/107 (67.5/32.5%), 6.6%, and 10.5%, respectively. Median OS, CSS, and RFS were 220.6, 220.6, and 147.1 months, respectively. The multivariable analysis showed that pathologic T stage and Fuhrman nuclear grade were significantly associated with OS and CSS. Pathologic T stage and tumor size were associated with RFS. After adjusting for these significant prognostic clinicopathological factors, Ki-67 was significantly associated with OS (hazard ratio [HR], 2.7), CSS (HR, 3.82), and RFS (HR, 4.85) and pS6 was associated with CSS (HR, 8.63) and RFS (HR, 8.51) in the multivariable model (p<0.05). Conclusion pS6 and Ki-67 are significant prognostic factors of RCC; however, BAP1, PBRM1, TGase 2, PD-L1, CA9, PTEN loss, and PSMA markers did not show this association.

show abstract

Regional Geographic Variations in Kidney Cancer Incidence Rates in European Countries

Cited by 62 publications

References 14 publications

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

Understanding treatment disconnect and mortality trends in renal cell carcinoma using tumor registry data.

The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry

Contact Info

Product

Resources

About